TAO Synergies (TAOX) Goodwill & Intangibles (2025 - 2026)
TAO Synergies' (TAOX) quarterly Goodwill & Intangibles came in at $16.8 million in Q2 2026, up 274.74% on a YoY basis from $4.5 million in Q2 2025, and down 33.18% quarter-over-quarter from $25.2 million in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) Goodwill & Intangibles (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Goodwill & Intangibles for 2 consecutive years, with $16.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Goodwill & Intangibles rose 274.74% year-over-year to $16.8 million; the trailing twelve-month figure through Jun 2026 stood at $16.8 million (up 274.74% YoY), and the FY2025 full-year result was $17.9 million, changed N/A from the prior year.
- Goodwill & Intangibles eased to $16.8 million in Q2 2026 per TAOX's latest filing, from $25.2 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $25.2 million in Q1 2026 and bottomed at $4.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.81 Mn |
| Mar 31, 2026 | 25.16 Mn |
| Dec 31, 2025 | 17.93 Mn |
| Sep 30, 2025 | 15.38 Mn |
| Jun 30, 2025 | 4.49 Mn |